Immunome (NASDAQ:IMNM) Shares Gap Up – What’s Next?

Shares of Immunome, Inc. (NASDAQ:IMNM) gapped up before the market opened on Monday . The stock had previously closed at $19.57, but opened at $22.92. Immunome shares last traded at $24.8180, with a volume of 3,207,663 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Craig Hallum started coverage on Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 price target on the stock. Guggenheim upped their target price on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. The Goldman Sachs Group started coverage on Immunome in a research report on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target for the company. Truist Financial initiated coverage on shares of Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and a consensus price target of $30.09.

Immunome Stock Up 3.7%

The business’s fifty day moving average price is $17.30 and its 200 day moving average price is $12.49. The firm has a market capitalization of $2.15 billion, a PE ratio of -7.96 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, sell-side analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IMNM. MetLife Investment Management LLC grew its position in Immunome by 19.1% during the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock valued at $285,000 after acquiring an additional 6,792 shares during the period. Tema Etfs LLC acquired a new stake in shares of Immunome in the second quarter worth $1,074,000. Kennedy Capital Management LLC increased its position in shares of Immunome by 642.6% in the second quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock worth $1,017,000 after acquiring an additional 94,627 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Immunome by 55.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock valued at $5,216,000 after acquiring an additional 275,000 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in shares of Immunome by 17.8% during the 2nd quarter. Intech Investment Management LLC now owns 40,565 shares of the company’s stock valued at $377,000 after acquiring an additional 6,141 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.